Matthew L. Hemming

2.2k total citations
25 papers, 1.6k citations indexed

About

Matthew L. Hemming is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Matthew L. Hemming has authored 25 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 7 papers in Physiology. Recurrent topics in Matthew L. Hemming's work include Sarcoma Diagnosis and Treatment (11 papers), Alzheimer's disease research and treatments (6 papers) and Gastrointestinal Tumor Research and Treatment (5 papers). Matthew L. Hemming is often cited by papers focused on Sarcoma Diagnosis and Treatment (11 papers), Alzheimer's disease research and treatments (6 papers) and Gastrointestinal Tumor Research and Treatment (5 papers). Matthew L. Hemming collaborates with scholars based in United States, United Kingdom and Germany. Matthew L. Hemming's co-authors include Dennis J. Selkoe, Joshua E. Elias, Steven P. Gygi, Wesley Farris, Gary B. Quistad, Chandrajit P. Raut, Christopher J. Winrow, Carrolee Barlow, John E. Casida and Ewa Sicińska and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Matthew L. Hemming

25 papers receiving 1.5k citations

Peers

Matthew L. Hemming
Amee J. George Australia
Brigitte Fournier Switzerland
Yunzhou Dong United States
Noriaki Kinoshita Japan
Nabil Hajji United Kingdom
Ju Gao China
Jeffrey J. Legos United States
Agnieszka Gizak Poland
Yasushi Fujitani Japan
Zhihua Qiu China
Amee J. George Australia
Matthew L. Hemming
Citations per year, relative to Matthew L. Hemming Matthew L. Hemming (= 1×) peers Amee J. George

Countries citing papers authored by Matthew L. Hemming

Since Specialization
Citations

This map shows the geographic impact of Matthew L. Hemming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew L. Hemming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew L. Hemming more than expected).

Fields of papers citing papers by Matthew L. Hemming

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew L. Hemming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew L. Hemming. The network helps show where Matthew L. Hemming may publish in the future.

Co-authorship network of co-authors of Matthew L. Hemming

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew L. Hemming. A scholar is included among the top collaborators of Matthew L. Hemming based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew L. Hemming. Matthew L. Hemming is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kola, Vijaya S.R., et al.. (2024). ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs. Cancer Research. 84(14). 2247–2264. 2 indexed citations
2.
Hemming, Matthew L., Patrick Bhola, Leona A. Doyle, et al.. (2022). Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. Clinical Cancer Research. 28(11). 2397–2408. 6 indexed citations
3.
Hemming, Matthew L., Shannon Coy, Jia‐Ren Lin, et al.. (2021). HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. Clinical Cancer Research. 27(6). 1706–1719. 17 indexed citations
4.
5.
Hemming, Matthew L., Changyu Fan, Chandrajit P. Raut, et al.. (2020). Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. Molecular Cancer Research. 18(9). 1302–1314. 22 indexed citations
6.
Hemming, Matthew L., Matthew A. Lawlor, Timothy Hagan, et al.. (2019). Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Research. 79(5). 994–1009. 21 indexed citations
7.
Flavahan, William, Yotam Drier, Sarah E. Johnstone, et al.. (2019). Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 575(7781). 229–233. 169 indexed citations
8.
Hemming, Matthew L., Kelly Klega, Justin Rhoades, et al.. (2019). Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease. JCO Precision Oncology. 2019(3). 1–11. 46 indexed citations
9.
Hemming, Matthew L., Michael C. Heinrich, Sebastian Bauer, & Suzanne George. (2018). Translational insights into gastrointestinal stromal tumor and current clinical advances. Annals of Oncology. 29(10). 2037–2045. 30 indexed citations
10.
Hemming, Matthew L., Matthew A. Lawlor, Rhamy Zeid, et al.. (2018). Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proceedings of the National Academy of Sciences. 115(25). E5746–E5755. 26 indexed citations
11.
Brien, Gerard L., David Remillard, Junwei Shi, et al.. (2018). Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. eLife. 7. 148 indexed citations
12.
Hemming, Matthew L., Kelly Klega, Anwesha Nag, et al.. (2018). Identification of leiomyosarcoma circulating tumor DNA through ultra-low passage whole genome sequencing and correlation with tumor burden: A pilot experience.. Journal of Clinical Oncology. 36(15_suppl). 11565–11565. 2 indexed citations
13.
Hemming, Matthew L., Andrew J. Wagner, Marisa R. Nucci, et al.. (2017). YWHAE -rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. Gynecologic Oncology. 145(3). 531–535. 26 indexed citations
14.
Hemming, Matthew L., Joshua E. Elias, Steven P. Gygi, & Dennis J. Selkoe. (2009). Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics. PLoS ONE. 4(12). e8477–e8477. 154 indexed citations
15.
Hemming, Matthew L., Joshua E. Elias, Steven P. Gygi, & Dennis J. Selkoe. (2008). Proteomic Profiling of γ-Secretase Substrates and Mapping of Substrate Requirements. PLoS Biology. 6(10). e257–e257. 136 indexed citations
16.
Hemming, Matthew L., Dennis J. Selkoe, & Wesley Farris. (2007). Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease. Neurobiology of Disease. 26(1). 273–281. 102 indexed citations
17.
Hemming, Matthew L., Michaela Patterson, Casper Reske-Nielsen, et al.. (2007). Reducing Amyloid Plaque Burden via Ex Vivo Gene Delivery of an Aβ-Degrading Protease: A Novel Therapeutic Approach to Alzheimer Disease. PLoS Medicine. 4(8). e262–e262. 101 indexed citations
18.
Hemming, Matthew L. & Dennis J. Selkoe. (2005). Amyloid β-Protein Is Degraded by Cellular Angiotensin-converting Enzyme (ACE) and Elevated by an ACE Inhibitor. Journal of Biological Chemistry. 280(45). 37644–37650. 271 indexed citations
19.
Winrow, Christopher J., et al.. (2003). Loss of neuropathy target esterase in mice links organophosphate exposure to hyperactivity. Nature Genetics. 33(4). 477–485. 135 indexed citations
20.
Hemming, Matthew L., et al.. (1996). Ocular and dermal irritation studies of some quaternary ammonium compounds. Food and Chemical Toxicology. 34(2). 177–182. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amee J. George Breakdown of academic impact, for papers by Brigitte Fournier Breakdown of academic impact, for papers by Yunzhou Dong Breakdown of academic impact, for papers by Noriaki Kinoshita Breakdown of academic impact, for papers by Nabil Hajji Breakdown of academic impact, for papers by Ju Gao Breakdown of academic impact, for papers by Jeffrey J. Legos Breakdown of academic impact, for papers by Agnieszka Gizak Breakdown of academic impact, for papers by Yasushi Fujitani Breakdown of academic impact, for papers by Zhihua Qiu
Rankless by CCL
2026